Lundbeck announced the acceptance of its new drug application (NDA) for Vyepti (eptinezumab) by the Ministry of Health, Labor and Welfare (MHLW) in Japan. The submission reflects the… read more.
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Ajovy (fremanezumab-vfrm) to expand the… read more.
Atogepant, an oral drug approved to prevent migraine, appears to also alleviate migraine symptoms early after onset has begun. The findings were reported on December 23, 2024 in… read more.
A recent longitudinal study from the University of Toronto reveals the mental health consequences of the COVID-19 pandemic on older adults living with migraine. Using a sample of… read more.
Lundbeck announced that Vyepti (eptinezumab) met the primary and all key secondary endpoints in SUNRISE, a phase III pivotal trial predominantly conducted in Asia evaluating the efficacy and… read more.
Treatment with ubrogepant at the first sign of migraine onset appears to help prevent acute symptoms from developing. Researchers reported their findings on August 28 in Neurology. Author… read more.
A new analysis of data from a large study of women’s health shows no link between a history of migraine and the risk of developing Parkinson’s disease (PD)…. read more.
A drug used to prevent migraine may also be effective in people with migraine who experience rebound headaches, according to a new study published in the June 26,… read more.
28th EAHP Congress Highlights No fewer than 11 posters from Spanish pharmacists dealt with the use of monoclonal antibodies in the management of migraine. Anti-CGRP (calcitonin gene-related peptide)… read more.
For middle-aged women plagued by migraines, or hot flashes and night sweats, another worry may linger in the backs of their minds: whether these experiences have set them… read more.
Triptan, ergot and anti-emetic medications appear to be two to five times more effective than ibuprofen for treating migraine, researchers reported on Nov. 29, 2023 in Neurology. “There… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
